Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts

Arthritis Research and Therapy

Volumn 8, Issue 5, 2006, Pages

  Komano, Yukiko ^a   Nanki, Toshihiro ^a   Hayashida, Kenji ^b   Taniguchi, Ken ^c   Nobuyuki, Miyasaka ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b HOSHIGAOKA KOSEINENKIN HOSPITAL   (Japan)

^c TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; CELL SURFACE RECEPTOR; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; CYCLO(ARGINYL-GLYCYL-ASPARTYL-PHENYLALANYL-VALYL); CYCLOPEPTIDE; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN RECEPTOR; INTEGRIN; INTEGRIN ALPHAVBETA1; INTERLEUKIN 6; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NFATC1 PROTEIN, HUMAN; OSTEOCLAST DIFFERENTIATION FACTOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SIRPB1 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TYROBP PROTEIN, HUMAN; VITRONECTIN RECEPTOR;

CELL CULTURE; CELL DIFFERENTIATION; CLASSIFICATION; COMPLICATION; CYTOLOGY; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MONOCYTE; OSTEOCLAST; OSTEOPOROSIS; PATHOLOGY; RHEUMATOID ARTHRITIS; SYNOVIUM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GPI-LINKED PROTEINS; HUMANS; INTEGRIN BETA3; INTEGRINS; INTERLEUKIN-6; MACROPHAGE COLONY-STIMULATING FACTOR; MEMBRANE PROTEINS; MONOCYTES; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOPOROSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES, CYCLIC; RANK LIGAND; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTORS, CELL SURFACE; RECEPTORS, IGG; RECEPTORS, IMMUNOLOGIC; RECEPTORS, VITRONECTIN; RNA, SMALL INTERFERING; SYNOVIAL MEMBRANE; TNF RECEPTOR-ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247551130     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2046     Document Type: Article

References (55)

1. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699.
2. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G: Osteoclasts are essential for TNF-a-mediated joint destruction. J Clin Invest 2002, 110:1419-1427.
3. Walsh NC, Crotti TN, Goldring SR, Gravallese EM: Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005, 208 228-251.
4. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ, Suda TM Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells Proc Natl Acad Sci USA 1990, 87:7260-7264.
5. Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, Davy E, Shimamoto G, Beck J, Kaufman SA, et al.: Characterization of osteoclast precursors in human blood. Br J Haematol 2000, 111:501-512.
6. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM: Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821-831.
7. Li P, Schwarz EM, O'Keefe RJ, Ma L, Looney RJ, Ritchlin CT, Boyce BF, Xing L: Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum 2004, 50:265-276.
8. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S: Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000, 43:2523-2530.
9. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA: The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996, 137:4058-4060.
10. Fujikawa Y, Sabokbar A, Neale S, Athanasou NA: Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis 1996, 55:816-822.
11. Ancuta P, Rao R, Moses A, Mehle A, Shaw SK, Luscinskas FW, Gabuzda D: Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003, 197:1701-1707.
12. Geissmann F, Jung S, Littman DR: Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
13. Krutzik SR, Tan B, Li H, Ochoa MT, Liu PT, Sharfstein SE, Graeber TG, Sieling PA, Liu YJ, Rea TH, et al.: TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells Nat Med 2005, 11:653-660.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
15. Ziegler-Heitbrock HW: HeterogeneitT of human blood monocytes: the CD14+CD16+ subpopulation. Immunol Today 1996, 17:424-428.
16. Takayanagi H: Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005, 83:170-179.
17. Hynes ROB Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
18. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M: Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-?B ligand (RANKL). J Biol Chem 2000, 275:31155-31161.
19. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, Choi Y: TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999, 4 1041-1049.
20. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, Suda T, Takahashi N: p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002, 143:3105-3113.
21. Helfrich MH, Nesbitt SA, Dorey EL, Horton MA: Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a β3 integrin J Bone Miner Res 1992, 7:335-343.
22. Shono T, Mochizuki Y, Kanetake H, Kanda S: Inhibition of FGF-2- mediated chemotaxis of murine brain capillary endothelial cells by cyclic RGDfV peptide through blocking the redistribution of c-Src into focal adhesions. Exp Cell Res 2001, 268:169-178.
23. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, et al.: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3 889-901.
24. Hayashida K, Nanki T, Girschick H, Yavuz S, Ochi T, Lipsky PE: Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Arthritis Res 2001, 3 118-126.
25. Teitelbaum SL: Osteoclasts, integrins, and osteoporosis. J Bone Miner Metab 2000, 18:344-349.
26. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL: Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000, 105:433-440.
27. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL: c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation. J Clin Invest 2003, 111:749-758.
28. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, Pando MP, Asano T, Verma IM, Oda H, et al.: Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J Cell Biol 2000, 148:333-342.
29. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, WagnAr EF: c-Fos: a key regulator of osteoclastmacrophage lineage determination and bone remodeling. Science 1994, 266 443-448.
30. Nakamura I, Tanaka H, Rodan GA, Duong LT: Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. Endocrinology 1998, 139:5182-5193.
31. Murphy MG, Cerchio K, Stoch SA, Gottesdiener K, Wu M, Recker R: Effect of L-000845704 an αvβ3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women J Clin Endocrinol Metab 2005, 90:2022-2028.
32. Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG, Teitelbaum SL: A peptidomimetic antagonist of the αvβ3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 1997, 99:2284-2292.
33. Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M: Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD -containing protein. Endocrinology 1993, 132:1411-1413.
34. Badger AM, Blake S, Kapadia R, Sarkar S, Levin J, Swift BA, Hoffman SJ, Stroup GB, Miller WH, Gowen M, Lark MW: Diseasemodifying activity of SB 273005 an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvantinduced arthritis. Arthritis Rheum 2001, 44:128-137.
35. Horton MA, Massey HM, Rosenberg N, Nicholls B, Seligsohn U, Flanagan AM: Upregulation of osteoclast Α2β1 integrin compensates for lack of αvβ3 vitronectin receptor in Iraqi-Jewishtype Glanzmann thrombasthenia. Br J Haematol 2003, 122:950-957.
36. Nesbitt S, Nesbit A, Helfrich M, Horton M: Biochemical characterization of human osteoclast integrins. Osteoclasts express αvβ3, α2β1, and αvβ1 integrins. J Biol Chem 1993, 268:16737-16745.
37. Roodman GD: AdvancesTin bone biology: the osteoclast. Endocr Rev 1996, 17:308-332.
38. NimmerjahnOF, Ravetch JV: Fcγ receptors: old friends and new family members. Immunity 2006, 24:19-28.
39. Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP: NFATc1 directly induces the human b3 integrin gene in osteoclast differentiation. J Musculoskelet Neuronal Interact 2005, 5 335-337.
40. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L: The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002, 168 3536-3542.
41. Katayama K, Matsubara T, Fujiwara M, Koga M, Furukawa S: CD14+CD16+ monocyte subpopulation in Kawasaki disease. Clin Exp Immunol 2000, 121:566-570.
42. Kawanaka N, Yamamura M, Aita T, Morita Y, Okamoto A, Kawashima M, Iwahashi M, Ueno A, Ohmoto Y, Makino H: CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum 2002, 46:2578-2586.
43. Fingerle G, Pforte A, Passlick B, Blumenstein M, Strobel M, Ziegler- Heitbrock HW: The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. Blood 1993, 82:3170-3176.
44. Saleh MN, Goldman SJ, LoBuglio AF, Beall AC, Sabio H, McCord MC, Minasian L, Alpaugh RK, Weiner LM, Munn DH: CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 1995, 85:2910-2917.
45. Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, Leenen PJ: Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004, 172:4410-4417.
46. Kruger M, Van de Winkel JG, De Wit TP, Coorevits L, Ceuppens JL: Granulocyte-macrophage colony-stimulating factor downregulates CD14 expression on monocytes. Immunology 1996, 89:89-95.
47. Blom AB, Radstake TR, Holthuysen AE, Sloetjes AW, Pesman GJ, Sweep FG, van de Loo FA, Joosten LA, Barrera P, van Lent PL, van den Berg WB: Increased expression of Fc? receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor a and matrix metalloproteinase. Arthritis Rheum 2003, 48:1002-1014.
48. Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T, Miyasaka N: Inhibition of fractalkine ameliorates murine collagen- induced arthritis. J Immunol 2004, 173:7010-7016.
49. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, et al.: Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44:1003-1012.
50. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR: Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000, 43:250-258.
51. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S: Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000, 43:259-269.
52. Seitz M, Loetscher P, Fey MF, Tobler A: Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol 1994, 33:613-619.
53. Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis factor a in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991, 34:1125-1132.
54. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S: Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclastlike cell formation. J Bone Miner Res 1996, 11:88-95.
55. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, et al.: Tumor necrosis factor a stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191:275-286.